Sangamo Reports Presentation of New Data from Proprietary ZFP Therapeutic Programs for Lysosomal Storage Disorders at ASGCT

By: via Benzinga
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that new data from the company's proprietary ZFP Therapeutic® programs in disease ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.